Drug Profile
Research programme: PAR2 modulators - UniQuest
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator University of Queensland
- Developer UniQuest; University of Queensland
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action PAR 2 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Inflammation; Metabolic syndrome
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in Australia (PO)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Inflammation in Australia (PO)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Metabolic-syndrome in Australia (PO)